Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | EPHB3 | P54753 | 3/20 | 0.45 |
| ▸ | CLK1 | P49759 | 4/20 | 0.42 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethane SCHEMBL18642128 | 0.97 | TGFBR1 (0.48) | TGFBR1RAB9ANPC1POLBEPHB3 | |
| SCHEMBL312556 | 0.87 | EPHB3 (0.56) | TGFBR1RAB9ANPC1EPHB3CLK1 | |
| SCHEMBL29544124 | 0.85 | POLB (0.49) | TGFBR1RAB9ANPC1POLBEPHB3 | |
| Hydrochloric Acid SCHEMBL1203294 | 0.81 | POLB (0.46) | TGFBR1RAB9ANPC1POLBEPHB3 | |
| SCHEMBL9753957 | 0.81 | KDM4E (0.50) | TGFBR1RAB9ANPC1EPHB3CLK1 | |
| SCHEMBL27077073 | 0.81 | TGFBR1 (0.48) | TGFBR1EPHB3CLK1TGFBR2 | |
| SCHEMBL2817471 | 0.79 | ADORA2A (0.54) | TGFBR1TGFBR2KDM4E | |
| SCHEMBL14740380 | 0.79 | TGFBR1 (0.53) | TGFBR1POLBCLK1TGFBR2ALDH1A1 | |
| SCHEMBL14756587 | 0.79 | TGFBR1 (0.48) | TGFBR1EPHB3CLK1TGFBR2 | |
| SCHEMBL1649588 | 0.79 | TGFBR1 (0.47) | TGFBR1EPHB3CLK1TGFBR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219893-A1 | Krüppel-Like Factor 15 (KLF15) Small Molecule Agonists in Kidney Disease | US GOV VETERANS AFFAIRS (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230219893-A1 | Krüppel-Like Factor 15 (KLF15) Small Molecule Agonists in Kidney Disease | US GOV VETERANS AFFAIRS (US) | 2023-07-13 | — | — | US | disclosed |
| US-11643394-B2 | Krüppel-like factor 15 (KLF15) small molecule agonists in kidney disease | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643394-B2 | Krüppel-like factor 15 (KLF15) small molecule agonists in kidney disease | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-05-09 | — | — | US | disclosed |
| US-20230122219-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| EP-4100004-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20210347734-A1 | Krüppel-Like Factor 15 (KLF15) Small Molecule Agonists in Kidney Disease | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2021-11-11 | — | — | US | disclosed |
| WO-2021222637-A1 | KRÜPPEL-LIKE FACTOR 15 (KLF15) SMALL MOLECULE AGONISTS IN KIDNEY DISEASE | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021158634-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021158634-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| US-20180042902-A1 | Heterocyclic Compounds and Uses Thereof | INTELLIKINE, LLC | 2018-02-15 | — | — | US | disclosed |
| US-20180042902-A1 | Heterocyclic Compounds and Uses Thereof | INTELLIKINE, LLC | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643394-B2 | Krüppel-like factor 15 (KLF15) small molecule agonists in kidney disease | KIF15, KLF5, KLF10 | TGFBR1 1792/4885RAB9A 1697/4885NPC1 834/4885 |
| US-20230219893-A1 | Krüppel-Like Factor 15 (KLF15) Small Molecule Agonists in Kidney Disease | KIF15, KLF5, KLF10 | TGFBR1 1792/4885RAB9A 1697/4885NPC1 834/4885 |
| US-20210347734-A1 | Krüppel-Like Factor 15 (KLF15) Small Molecule Agonists in Kidney Disease | KIF15, KLF5, KLF10 | TGFBR1 1792/4885RAB9A 1697/4885NPC1 834/4885 |
| US-20230122219-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TGFBR1 1014/4885RAB9A 4270/4885NPC1 3159/4885 |
| US-20180042902-A1 | Heterocyclic Compounds and Uses Thereof | PIK3CA, PIK3CD, PIK3CB | TGFBR1 4355/4885RAB9A 758/4885NPC1 1284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.